Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation enables accurate assessment of HER2 genomic status in ovarian tumours

Benedict Yan; Shoa Nian Choo; Patricia Mulyadi; Supriya Srivastava; Chee Wee Ong; Kol Jia Yong; Thomas Putti; Manuel Salto-Tellez; Gkeok Stzuan Diana Lim

doi:10.1136/jclinpath-2011-200082

Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation enables accurate assessment of HER2 genomic status in ovarian tumours

Benedict Yan, Shoa Nian Choo, Patricia Mulyadi, Supriya Srivastava, Chee Wee Ong, Kol Jia Yong, Thomas Putti, Manuel Salto-Tellez, Gkeok Stzuan Diana Lim

Research output: Contribution to journal › Article › peer-review

21 Citations (Scopus)

Abstract

Ovarian cancer is a leading cause of gynaecological cancer-related morbidity and mortality. There has been increasing interest in the potential utility of anti-human epidermal growth factor receptor 2 (anti-HER2) agents in the treatment of this disease, with the attendant need to identify suitable predictive biomarkers of response to treatment.

Original language	English
Pages (from-to)	1097-101
Number of pages	5
Journal	Journal of Clinical Pathology
Volume	64
Issue number	12
DOIs	https://doi.org/10.1136/jclinpath-2011-200082
Publication status	Published - Dec 2011

Keywords

Sensitivity and Specificity
Chromosomes, Human, Pair 17
Ovarian Neoplasms
Genes, erbB-2
Receptor, erbB-2
Humans
Color
Gene Amplification
In Situ Hybridization
Adenocarcinoma, Mucinous
Cohort Studies
Immunohistochemistry
Female

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1136/jclinpath-2011-200082

Cite this

Yan, Benedict ; Choo, Shoa Nian ; Mulyadi, Patricia ; Srivastava, Supriya ; Ong, Chee Wee ; Yong, Kol Jia ; Putti, Thomas ; Salto-Tellez, Manuel ; Lim, Gkeok Stzuan Diana. / Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation enables accurate assessment of HER2 genomic status in ovarian tumours. In: Journal of Clinical Pathology. 2011 ; Vol. 64, No. 12. pp. 1097-101.

@article{409c929865974d21baf376f99311a1c4,

title = "Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation enables accurate assessment of HER2 genomic status in ovarian tumours",

abstract = "Ovarian cancer is a leading cause of gynaecological cancer-related morbidity and mortality. There has been increasing interest in the potential utility of anti-human epidermal growth factor receptor 2 (anti-HER2) agents in the treatment of this disease, with the attendant need to identify suitable predictive biomarkers of response to treatment.",

keywords = "Sensitivity and Specificity, Chromosomes, Human, Pair 17, Ovarian Neoplasms, Genes, erbB-2, Receptor, erbB-2, Humans, Color, Gene Amplification, In Situ Hybridization, Adenocarcinoma, Mucinous, Cohort Studies, Immunohistochemistry, Female",

author = "Benedict Yan and Choo, {Shoa Nian} and Patricia Mulyadi and Supriya Srivastava and Ong, {Chee Wee} and Yong, {Kol Jia} and Thomas Putti and Manuel Salto-Tellez and Lim, {Gkeok Stzuan Diana}",

year = "2011",

month = dec,

doi = "10.1136/jclinpath-2011-200082",

language = "English",

volume = "64",

pages = "1097--101",

journal = "Journal of Clinical Pathology",

issn = "0021-9746",

publisher = "BMJ Publishing Group",

number = "12",

}

Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation enables accurate assessment of HER2 genomic status in ovarian tumours. / Yan, Benedict; Choo, Shoa Nian; Mulyadi, Patricia; Srivastava, Supriya; Ong, Chee Wee; Yong, Kol Jia; Putti, Thomas; Salto-Tellez, Manuel; Lim, Gkeok Stzuan Diana.

In: Journal of Clinical Pathology, Vol. 64, No. 12, 12.2011, p. 1097-101.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation enables accurate assessment of HER2 genomic status in ovarian tumours

AU - Yan, Benedict

AU - Choo, Shoa Nian

AU - Mulyadi, Patricia

AU - Srivastava, Supriya

AU - Ong, Chee Wee

AU - Yong, Kol Jia

AU - Putti, Thomas

AU - Salto-Tellez, Manuel

AU - Lim, Gkeok Stzuan Diana

PY - 2011/12

Y1 - 2011/12

N2 - Ovarian cancer is a leading cause of gynaecological cancer-related morbidity and mortality. There has been increasing interest in the potential utility of anti-human epidermal growth factor receptor 2 (anti-HER2) agents in the treatment of this disease, with the attendant need to identify suitable predictive biomarkers of response to treatment.

AB - Ovarian cancer is a leading cause of gynaecological cancer-related morbidity and mortality. There has been increasing interest in the potential utility of anti-human epidermal growth factor receptor 2 (anti-HER2) agents in the treatment of this disease, with the attendant need to identify suitable predictive biomarkers of response to treatment.

KW - Sensitivity and Specificity

KW - Chromosomes, Human, Pair 17

KW - Ovarian Neoplasms

KW - Genes, erbB-2

KW - Receptor, erbB-2

KW - Humans

KW - Color

KW - Gene Amplification

KW - In Situ Hybridization

KW - Adenocarcinoma, Mucinous

KW - Cohort Studies

KW - Immunohistochemistry

KW - Female

U2 - 10.1136/jclinpath-2011-200082

DO - 10.1136/jclinpath-2011-200082

M3 - Article

C2 - 21896578

VL - 64

SP - 1097

EP - 1101

JO - Journal of Clinical Pathology

JF - Journal of Clinical Pathology

SN - 0021-9746

IS - 12

ER -

Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation enables accurate assessment of HER2 genomic status in ovarian tumours

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this